InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Avalo Therapeutics, Inc.

AVTX Clue Score19
United States Fiscal year ends December CIK 0001534120 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Mostly scheduled

Individual transactions

35
Insider
Date
Role
Action
Shares
Price
Amount
Christopher Ryan Sullivan
16 Sep 2026
Chief Financial Officer
Sold after exercise
12,394
$16.33
$202.44K
Christopher Ryan Sullivan
10 Sep 2026
Chief Financial Officer
Sold after exercise
10,185
$17.62
$179.46K
Mittie Doyle
28 Aug 2026
Chief Medical Officer
Sold after exercise
679
$20.00
$13.58K
Christopher Ryan Sullivan
18 Aug 2026
Chief Financial Officer
Sold after exercise
31,031
$20.05
$622.32K
Mittie Doyle
17 Aug 2026
Chief Medical Officer
Sold after exercise
1,000
$20.00
$20.00K
Christopher Ryan Sullivan
17 Aug 2026
Chief Financial Officer
Sold after exercise
3,749
$19.94
$74.76K
Christopher Ryan Sullivan
17 Aug 2026
Chief Financial Officer
Sold after exercise
37,945
$19.85
$753.33K
Mittie Doyle
10 Aug 2026
Chief Medical Officer
Sold after exercise
679
$20.00
$13.58K
Mittie Doyle
27 Jul 2026
Chief Medical Officer
Sold after exercise
1,000
$20.00
$20.00K
Mittie Doyle
30 Jun 2026
Chief Medical Officer
Sold after exercise
4,654
$20.00
$93.08K
Mittie Doyle
23 Jun 2026
Chief Medical Officer
Sold after exercise
1,450
$18.00
$26.10K
Mittie Doyle
28 May 2026
Chief Medical Officer
Sold after exercise
679
$16.00
$10.86K
Mittie Doyle
15 May 2026
Chief Medical Officer
Sold after exercise
3,000
$18.76
$56.28K
Christopher Ryan Sullivan
7 May 2026
Chief Financial Officer
Sold after exercise
18,606
$24.12
$448.82K
Mittie Doyle
6 May 2026
Chief Medical Officer
Sold after exercise
10,058
$22.88
$230.13K
Mittie Doyle
6 May 2026
Chief Medical Officer
Sold after exercise
19,015
$22.41
$426.05K
Mittie Doyle
6 May 2026
Chief Medical Officer
Sold after exercise
44,944
$21.20
$952.67K
Mittie Doyle
6 May 2026
Chief Medical Officer
Sold after exercise
5,000
$19.65
$98.25K
Mittie Doyle
6 May 2026
Chief Medical Officer
Sold after exercise
27,538
$18.03
$496.41K
Christopher Ryan Sullivan
6 May 2026
Chief Financial Officer
Sold after exercise
8,900
$22.57
$200.91K
Christopher Ryan Sullivan
6 May 2026
Chief Financial Officer
Sold after exercise
9,219
$21.37
$197.01K
Christopher Ryan Sullivan
6 May 2026
Chief Financial Officer
Sold after exercise
2,700
$20.76
$56.05K
Christopher Ryan Sullivan
6 May 2026
Chief Financial Officer
Sold after exercise
12,347
$19.28
$238.09K
Christopher Ryan Sullivan
6 May 2026
Chief Financial Officer
Sold after exercise
13,834
$18.55
$256.66K
Paul Varki
6 May 2026
Chief Legal Officer
Sold after exercise
400
$23.71
$9.48K
Paul Varki
6 May 2026
Chief Legal Officer
Sold after exercise
9,253
$22.70
$210.03K
Paul Varki
6 May 2026
Chief Legal Officer
Sold after exercise
22,839
$21.22
$484.54K
Paul Varki
6 May 2026
Chief Legal Officer
Sold after exercise
5,196
$19.78
$102.78K
Paul Varki
6 May 2026
Chief Legal Officer
Sold after exercise
37,375
$18.91
$706.84K
Mittie Doyle
5 May 2026
Chief Medical Officer
Sold after exercise
1,679
$16.00
$26.86K
Mittie Doyle
6 Apr 2026
Chief Medical Officer
Sold after exercise
3,970
$18.01
$71.51K
Mittie Doyle
1 Apr 2026
Chief Medical Officer
Sold after exercise
679
$16.00
$10.86K
Mittie Doyle
16 Mar 2026
Chief Medical Officer
Sold after exercise
25,492
$16.15
$411.61K
Jonathan Goldman
14 Nov 2025
Director
Sold after exercise
8,200
$14.35
$117.65K
Jonathan Goldman
14 Nov 2025
Director
Sold after exercise
3,167
$14.30
$45.29K
Show all 43 transactions →

What was left out

Form 4 filings counted 66
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 35
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 777,657
History held since 20 Oct 2015